LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

Home・Akciju saraksts・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Atvērts

SektorsVeselības aprūpe

56.91 1.77

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

55.84

Max

57.03

Galvenie mērījumi
By Trading Economics
Ienākumi	1.6B 2.7B
Pārdošana	-1B 11B
P/E Sektora vidējais	15.726 51.415
EPS	1.58
Dividenžu ienesīgums	4.45
Peļņas marža	23.309
Darbinieki	32,500
EBITDA	1.5B 3.7B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+13.89% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	4.45% 2.34%
Nākamie ieņēmumi	2026. g. 30. jūl.
Nākamais dividenžu datums	2026. g. 31. jūl.
Nākamais Ex dividenžu datums	2026. g. 2. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-4.3B 114B
Iepriekšējā atvēršanas cena	55.14
Iepriekšējā slēgšanas cena	56.91

Ziņu noskaņojums

By Acuity

43%

57%

138 / 346 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

N/A / 50.57 Atbalsts un pretestība

Bristol-Myers Squibb Co. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. maijs 06:42 UTC

Galvenie tirgus virzītāji

Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up

2026. g. 30. apr. 11:14 UTC

Peļņas

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

2026. g. 5. maijs 18:12 UTC

Peļņas

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

2026. g. 5. maijs 13:54 UTC

Peļņas

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb: Continue to See Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb: Reaffirming 2026 Financial Guidance With Total Revenue and Diluted EPS Trending Toward Upper End of Ranges >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb Backs 2026 Rev $46B-$47.5B >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q International Revenue Rose 11% to $3.7B >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb: 1Q Results Reflecting Sustained Momentum Across Our Growth Portfolio and Disciplined Execution Throughout the Business >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q U.S. Revenue Fell 1% to $7.79B >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q Rev $11.49B >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 1Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb: 1Q Growth Portfolio Revenue Increase Primarily Driven by Reblozyl, Camzyos and Breyanzi >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q Eliquis Revenue Rose 16% to $4.14B >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb Backs 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q Adjusted Gross Margin 70.3% >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 12% to $6.23B >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q EPS $1.31 >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 6% to $5.28B >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q Adj EPS $1.58 >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb: Latest 1Q Includes Net Impact of Loss of 3c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

2026. g. 30. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q Gross Margin 70.2% >BMY

2026. g. 14. apr. 14:13 UTC

Peļņas

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026. g. 14. apr. 12:57 UTC

Peļņas

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026. g. 14. apr. 11:19 UTC

Peļņas

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

2026. g. 14. apr. 10:34 UTC

Peļņas

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

2026. g. 13. apr. 21:23 UTC

Peļņas

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

2026. g. 6. febr. 12:35 UTC

Peļņas

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

2026. g. 5. febr. 15:25 UTC

Peļņas

Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Bristol-Myers Squibb Co. Prognoze

Cenas mērķis

By TipRanks

13.89% augšup

Prognoze 12 mēnešiem

Vidējais 64.29 USD 13.89%

Augstākais 75 USD

Zemākais 54 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Bristol-Myers Squibb Co. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

18 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 18 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Bristol-Myers Squibb Co. — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

N/A / 50.57Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Noskaņojums

By Acuity

138 / 346 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.